Conferences - Results from #60

Viewing 61-80 of 11872 articles

SUO 2024: The Efficacy of Salvage BCG for Recurrent Non-muscle Invasive Bladder Cancer After First-line Gemcitabine and Docetaxel

SUO 2024: Biparametric or Noncontrast Approach of MRI, Incorporating Bio Markers

SUO 2024: Mechanism of Action and Translation to the Clinic of Detalimogene Voraplasmid (EG-70) – A Novel, Investigational Non-Viral Immunotherapy for NMIBC

SUO 2024: Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk BCG-Unresponsive NMIBC with CIS

SUO 2024: Top Papers in Testicular Cancer 2024

SUO 2024: Trial Design for BCG Unresponsive NMIBC: Time to Move Past Single Arm Registration Trials?

SUO 2024: Setting the Stage – Overview of Emerging Intravesical Therapy Options: Mechanism of Action, Efficacy, Tolerability, Financial Considerations/Access

SUO 2024: Spotting Metastatic Masqueraders: How to Avoid Inappropriate Chemotherapy Administration for Testicular Cancer

SUO 2024: Phase III MK-5684-004 Study of CYP11A1 Inhibitor Opevesostat versus Next-generation Hormonal Agent Switch in Patients with Metastatic Castration-resistant Prostate Cancer after 1 Prior Next-generation Hormonal Agent

SUO 2024: Advances in RCC Molecular Imaging and Theranostics

SUO 2024: Evaluation of Response to 177Lu-PSMA-617 by Site Specific Disease in Metastatic Castrate-Resistant Prostate Cancer

SUO 2024: Updates to Testicular Cancer Epidemiology

SUO 2024: Artificial Intelligence in RCC Diagnosis and Treatment

SUO 2024: In-Depth Characterization of the Safety Profile of Belzutifan Monotherapy in Patients with Renal Cell Carcinoma: A Pooled Analysis of Four Clinical Trials

SUO 2024: Strategies for RPLND in Metastatic Testicular Seminoma

CG Oncology Announces Bond-003 Topline Results

SUO 2024: Adjuvant Systemic Therapy in Urothelial Carcinoma: Where Are We At Today?

SUO 2024: Disease-Free Survival and Overall Survival in Patients with High-Risk Muscle-Invasive Bladder Cancer Who Have Persistent Circulating Tumor DNA-Negative Biomarker Status Post-Cystectomy: IMvigor011 Study Surveillance Analysis

SUO 2024: Real-World Treatment and Clinical Outcomes in Patients with mCRPC Treated with Olaparib in the United States

SUO 2024: State of the Art Lecture: Controversies in the Surgical Management of Seminoma – Patient Selection for Primary RPLND

1
2
3
4
5
6
7
8
9
10